REBECCA Real-world Early BrEast CanCer mAnagement (REBECCA)

August 24, 2026 updated by: AstraZeneca

REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
126

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
    • Auvergne-Rh ne-Alpes
      • Clermont-Ferrand, Auvergne-Rh ne-Alpes, France, 63050
        • Recruiting
        • Research Site
      • Gleizé, Auvergne-Rh ne-Alpes, France, 69400
        • Recruiting
        • Research Site
      • Grenoble, Auvergne-Rh ne-Alpes, France, 38000
        • Not yet recruiting
        • Research Site
      • Lyon, Auvergne-Rh ne-Alpes, France, 69317
        • Recruiting
        • Research Site
      • Metz-Tessy, Auvergne-Rh ne-Alpes, France, 74370
        • Recruiting
        • Research Site
      • Saint-Etienne, Auvergne-Rh ne-Alpes, France, 42030
        • Not yet recruiting
        • Research Site
      • Saint-Priest-en-Jarez, Auvergne-Rh ne-Alpes, France, 42271
        • Not yet recruiting
        • Research Site
      • Thonon-les-Bains, Auvergne-Rh ne-Alpes, France, 74200
        • Recruiting
        • Research Site
      • Valence, Auvergne-Rh ne-Alpes, France, 26000
        • Recruiting
        • Research Site
      • Valence, Auvergne-Rh ne-Alpes, France, 26953
        • Not yet recruiting
        • Research Site
    • Bourgogne-Franche-Comt
      • Dijon, Bourgogne-Franche-Comt, France, 21079
        • Not yet recruiting
        • Research Site
    • Brittany Region
      • Plérin, Brittany Region, France, 22190
        • Recruiting
        • Research Site
      • Rennes, Brittany Region, France, 35042
        • Not yet recruiting
        • Research Site
      • Saint-Brieuc, Brittany Region, France, 22027
        • Not yet recruiting
        • Research Site
      • Saint-Grégoire, Brittany Region, France, 35768
        • Recruiting
        • Research Site
    • Centre-Val de Loire
      • Chambray-lès-Tours, Centre-Val de Loire, France, 37170
        • Recruiting
        • Research Site
      • Saint-Doulchard, Centre-Val de Loire, France, 18230
        • Recruiting
        • Research Site
    • Grand Est
      • Bezannes, Grand Est, France, 51430
        • Recruiting
        • Research Site
      • Haguenau, Grand Est, France, 67504
        • Not yet recruiting
        • Research Site
      • Nancy, Grand Est, France, 54100
        • Recruiting
        • Research Site
    • Hauts-de-France
      • Beauvais, Hauts-de-France, France, 60021
        • Recruiting
        • Research Site
      • Beuvry, Hauts-de-France, France, 62660
        • Recruiting
        • Research Site
      • Compiègne, Hauts-de-France, France, 60204
        • Not yet recruiting
        • Research Site
      • Creil, Hauts-de-France, France, 60109
        • Not yet recruiting
        • Research Site
      • Dechy, Hauts-de-France, France, 59187
        • Recruiting
        • Research Site
      • Lille, Hauts-de-France, France, 59020
        • Not yet recruiting
        • Research Site
      • Lille, Hauts-de-France, France, 59037
        • Not yet recruiting
        • Research Site
      • Saint-Martin-Boulogne, Hauts-de-France, France, 62280
        • Not yet recruiting
        • Research Site
      • Salouël, Hauts-de-France, France, 80054
        • Recruiting
        • Research Site
    • La R Union
      • Saint-Pierre-des-Corps, La R Union, France, 97448
        • Not yet recruiting
        • Research Site
    • Martinique
      • FORT de France Cedex, Martinique, France, 97261
        • Not yet recruiting
        • Research Site
    • New Aquitaine
      • Agen, New Aquitaine, France, 47923
        • Not yet recruiting
        • Research Site
      • Libourne, New Aquitaine, France, 33505
        • Not yet recruiting
        • Research Site
      • Limoges, New Aquitaine, France, 87042
        • Not yet recruiting
        • Research Site
      • Poitiers, New Aquitaine, France, 86021
        • Recruiting
        • Research Site
      • Périgueux, New Aquitaine, France, 24000
        • Recruiting
        • Research Site
    • Normandy
      • Caen, Normandy, France, 14000
        • Recruiting
        • Research Site
      • Rouen, Normandy, France, 76175
        • Recruiting
        • Research Site
    • Occitanie
      • Béziers, Occitanie, France, 34500
        • Not yet recruiting
        • Research Site
      • Montpellier, Occitanie, France, 34070
        • Recruiting
        • Research Site
      • Montpellier, Occitanie, France, 34298
        • Recruiting
        • Research Site
      • Nîmes, Occitanie, France, 30900
        • Recruiting
        • Research Site
      • Perpignan, Occitanie, France, 66046
        • Recruiting
        • Research Site
      • Toulouse, Occitanie, France, 31300
        • Recruiting
        • Research Site
    • Pays de la Loire Region
      • Nantes, Pays de la Loire Region, France, 44202
        • Not yet recruiting
        • Research Site
    • Provence-Alpes-C Te d'Azur
      • Avignon, Provence-Alpes-C Te d'Azur, France, 84918
        • Not yet recruiting
        • Research Site
      • Fréjus, Provence-Alpes-C Te d'Azur, France, 83608
        • Not yet recruiting
        • Research Site
      • Marseille, Provence-Alpes-C Te d'Azur, France, 13385
        • Not yet recruiting
        • Research Site
      • Nice, Provence-Alpes-C Te d'Azur, France, 06105
        • Not yet recruiting
        • Research Site
    • Île-de-France Region
      • Argenteuil, Île-de-France Region, France, 95107
        • Not yet recruiting
        • Research Site
      • Champigny-sur-Marne, Île-de-France Region, France, 94507
        • Recruiting
        • Research Site
      • Le Blanc-Mesnil, Île-de-France Region, France, 93150
        • Not yet recruiting
        • Research Site
      • Osny, Île-de-France Region, France, 95520
        • Recruiting
        • Research Site
      • Paris, Île-de-France Region, France, 75651
        • Recruiting
        • Research Site
      • Paris, Île-de-France Region, France, 75674
        • Recruiting
        • Research Site
      • Paris, Île-de-France Region, France, 75908
        • Not yet recruiting
        • Research Site
      • Paris, Île-de-France Region, France, 75970
        • Not yet recruiting
        • Research Site
      • Sarcelles, Île-de-France Region, France, 95200
        • Recruiting
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients will be recruited from about 60 participating sites to reach the target of 126 subjects, with a maximum of 60% of subtype TN overall.

Description

Inclusion Criteria:

  • Male or female aged ≥ 18 years
  • Patient diagnosed with HER2-negative eBC
  • Patient about to be initiated with adjuvant Olaparib at their physician's discretion
  • Patient has been informed and does not object to participation in the study.

Exclusion Criteria:

  • Patient not consenting to participate.
  • Patients included in the Early Access Program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Proportion of patients who receive Olaparib for the full treatment duration
Time Frame: 18 months after inclusion
The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.
18 months after inclusion

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
BRCA characteristics: Mutation type
Time Frame: 18 months after inclusion
Regarding BRCA characteristics: Mutation type: Tumoral (if only tumoral testing performed), somatic, germline.
18 months after inclusion
Type of variants
Time Frame: 18 months after inclusion
Type of variants: BRCA1 and/or BRCA2, PALB2 mutation, presence of other HRR gene mutations, presence of other mutations
18 months after inclusion
Medical history
Time Frame: 18 months after inclusion
Family and personal history of cancer/type
18 months after inclusion
Time to Olaparib treatment discontinuation
Time Frame: 18 months after inclusion
Time to Olaparib Treatment Discontinuation (TTD) or death
18 months after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
AstraZeneca

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 30, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 31, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 4, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 25, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 24, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • D0817R00068

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings